🌍Pumped to share that our article “Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology” is now out in TAMO! bit.ly/48XLEXo Laura Mezquita Miguel García Key findings below

🫁Lung cancer tops global mortality stats. Eastern Europe & Polynesia with 🔝 rates vs Sub-Saharan Africa with ⬇️ incidence

🚬 still the main risk factor globally ☢️ Population in radon prone areas face high risk of LC 🏭Outdoor pollution concerns LATAM, China or North Africa, among others 👷Occupational carcinogens still a relevant risk factor, mainly in male workers

🧬Genetic susceptibility may be involved in 2-14% LC cases across ethnic groups

🚨Our collaborative effort to characterize #MET kinase domain mutations as novel & targetable alterations in #NSCLC and other cancer types is out in Cancer Discovery! Led by💫scientists Federica Pecci & Seshiru Nakazawa Dana-Farber News OncoAlert #LCSM shorturl.at/huRT2 1/4🧵

If you are at #AACR24, stop by poster 21 (section 1) to learn more about the discovery of #ALK-specific #TCR clonotypes for the development of TCR-T cell therapies against ALK-positive cancers! Amazing study led by Carmen Mecca. Boston Children's Harvard Medical School ALK+ International

Glad to share our paper just published in Cancer Discovery that characterizes mutations in the MET kinase domain in lung cancer and other malignancies from a clinical, preclinical and structural point of view. doi.org/10.1158/2159-8…

Today, years of research & development have come to fruition in a new treatment option for small cell lung cancer, one of the most aggressive types of cancer. Amgen 🧪🔬🧬 ‘s T-cell engagers empowers the body’s immune system to specifically seek out and attack selective cancer cells.

Kicking off Treating Lung Cancer in Young Adults ready to start #ASCO24 with Laura Mezquita & Matteo Lambertini, MD PhD

Collecting data on patients lifestyle, environmental and family history of cancer can trigger measures to avoid continue carcinogen exposure for patients, their families, co-workers and general populations by Laura Mezquita #ASCO24

Asista al LALCA 2024 y descubra los avances en terapias contra el cáncer de pulmón, que abarcan ensayos clínicos en curso y diversos conocimientos sobre los principales avances preclínicos y clínicos tempranos. Obtenga perspectivas invaluables sobre cómo abordar las disparidades

We invite you to submit your abstracts on thoracic oncology and related sciences to LALCA 2024. We will be pleased to share knowledge related to the diagnosis and treatment of lung cancer, mesothelioma, and thymic neoplasms, as well as topics such as screening, oncological

We invite the thoracic oncology community to LALCA 2024, the integrated participation of everyone will be the difference in Bogota next November 2024 LUNGevity Foundation LungCancerRx 🫁💊 Lung Cancer Policy Network @LungCancerFaces LUNG FORCE EGFR Resisters EGFRm NSCLC EGFR Positive Lung Cancer UK ALK+ International

Registration is now open for the LALCA 2024 congress, which offers special prices for students, fellows, and non-medical personnel related to cancer and thoracic oncology. This is a unique opportunity to share and develop knowledge about lung cancer in Colombia and Latin America!

IASLC #lungcancer #lcsm

GANDALF: do NOT touch the palantír PIPPIN:

Tomorrow, July 31, is the last chance to submit your abstract for LALCA 2024 annual meetings! The 2024 Latin America Conference on Lung Cancer, taking place on November 14-16, in Bogota (Colombia). Go for it!!! lalca2024-iaslc.org/abstracts

I'm honored to join the phenomenal thoracic group Memorial Sloan Kettering Cancer Center as we continue working with the global oncology community to advance care for our patients worldwide with groundbreaking new discoveries and practice-changing therapies. #LCSM mskcc.org/news-releases/…

Important piece on supporting our international medical graduates (IMGs) in hematology/oncology. The IMGs I've had the pleasure of working with over the years have been among the best mentors, mentees, teachers, physicians, and researchers. ascopubs.org/doi/10.1200/OP…

We’re honored! 🏆 Amgen’s trailblazing innovation in small cell lung cancer (#SCLC) was named one of TIME’s Best Inventions of 2024. #TimeBestInventions